Search

Displaying results 2941 - 2950 of 10000 in total
  1. Drug

    Mumps virus strain B level jeryl lynn live antigen

    go.drugbank.com/drugs/DB10316
    ApprovedInvestigational

    It is an active immunization against mumps, which is a common childhood disease.

    Mixtures: Priorix Pulver in einer Durchstechflasche und Lösungsmittel in einer Fertigspritze zur Herstellung einer Injektionslösung, Priorix - Tetra Pulver in einer Durchstechflasche und Lösungsmittel in einer Fertigspritze zur Herstellung einer Injektionslösung
  2. Drug

    MK-8666

    go.drugbank.com/drugs/DB14937
    Investigational

    MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).

  3. Drug

    Xanthinol

    go.drugbank.com/drugs/DB09092
    ApprovedWithdrawn

    [L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy … [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing.

  4. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

    Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamine
  5. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.

  6. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    As of June 2020, a Phase 1/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity, and efficacy of the ad26.COV.S vaccine in 1045 healthy adults between the ages of 18-55 … The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745]

  7. Drug

    Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15620
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Fluarix Quadrivalent 2020/2021, VaxigripTetra Injektionssuspension in einer Fertigspritze
  8. Drug

    L-arginine

    go.drugbank.com/drugs/DB17289
    ApprovedInvestigationalNutraceutical

    Mixtures: Aminosyn II 8.5% M In 20% Dextrose (dual Chamber), Aminosyn II 7% M In 10% Dextrose(dual Chamber)
  9. Drug

    ABP-700

    go.drugbank.com/drugs/DB15411
    Investigational

    ABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy

  10. Drug

    MK-6325

    go.drugbank.com/drugs/DB15249
    Investigational

    MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).